Overview

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Evaluation of the diagnostic potential of HER2 imaging using zirconium 89 labelled trastuzumab.
Phase:
Phase 1
Details
Lead Sponsor:
Jules Bordet Institute
Treatments:
Trastuzumab